Zhang 2006.

Methods	Design: randomised, double‐blind, parallel groups 4 months
Participants	Country: China n=41 mild AD (DSM‐IV) Aged 47‐62 (55 +/‐0.4) years All menopause before age 65 Exclusion:dementia due to 'vessel, infection, toxication, metabolism, liver/kidney dysfunction or depression. All gave informed consent and had CT/MRI
Interventions	1. Beimeili (conjugated estrogen, Wyeth, USA) oral/1.25 mg /day 2. vit B1 20 mg 3x/day as Placebo
Outcomes	General Hasegawa Dementia Scale‐R (HDS‐R) ADL
Notes	HRT > vitamin B1 after 4 months on HDS‐R and ADL